Angela Alama

Genoa, 16132, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 55 publications

Extracellular vesicles miR-574-5p and miR-181a-5p as prognostic markers in NSCLC patients treated with nivolumab.

Extracellular vesicles miR-574-5p and miR-181a-5p as prognostic markers in NSCLC patients treated with nivolumab.

Journal: Clinical and experimental medicine

Published: April 12, 2024

Prognostic Role of Soluble and Extracellular Vesicle-Associated PD-L1, B7-H3 and B7-H4 in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors.

Prognostic Role of Soluble and Extracellular Vesicle-Associated PD-L1, B7-H3 and B7-H4 in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors.

Journal: Cells

Published: January 27, 2023

Immune Checkpoint Blockade: A Strategy to Unleash the Potential of Natural Killer Cells in the Anti-Cancer Therapy.

Immune Checkpoint Blockade: A Strategy to Unleash the Potential of Natural Killer Cells in the Anti-Cancer Therapy.

Journal: Cancers

Published: September 14, 2022

Immunotherapy-chemotherapy combinations for non-small cell lung cancer: current trends and future perspectives.

Immunotherapy-chemotherapy combinations for non-small cell lung cancer: current trends and future perspectives.

Journal: Expert opinion on biological therapy

Published: August 22, 2022

A Circulating Risk Score, Based on Combined Expression of Exo-miR-130a-3p and Fibrinopeptide A, as Predictive Biomarker of Relapse in Resectable Non-Small Cell Lung Cancer Patients.

A Circulating Risk Score, Based on Combined Expression of Exo-miR-130a-3p and Fibrinopeptide A, as Predictive Biomarker of Relapse in Resectable Non-Small Cell Lung Cancer Patients.

Journal: Cancers

Published: March 24, 2022

Serum levels of VCAM-1 are associated with survival in patients treated with nivolumab for NSCLC.

Serum levels of VCAM-1 are associated with survival in patients treated with nivolumab for NSCLC.

Journal: European journal of clinical investigation

Published: April 12, 2021

Safety and efficacy of immune checkpoint inhibitors in non-small-cell lung cancer: focus on challenging populations.

Safety and efficacy of immune checkpoint inhibitors in non-small-cell lung cancer: focus on challenging populations.

Journal: Immunotherapy

Published: February 25, 2021

Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer.

Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer.

Journal: International journal of molecular sciences

Published: February 14, 2021

Radiation-Related Deregulation of TUBB3 and BRCA1/2 and Risk of Secondary Lung Cancer in Women With Breast Cancer.

Radiation-Related Deregulation of TUBB3 and BRCA1/2 and Risk of Secondary Lung Cancer in Women With Breast Cancer.

Journal: Clinical breast cancer

Published: June 10, 2020

Radiomic Detection of EGFR Mutations in NSCLC.

Radiomic Detection of EGFR Mutations in NSCLC.

Journal: Cancer research

Published: March 27, 2020

ADP ribose polymerase inhibitors for treating non-small cell lung cancer: new additions to the pharmacotherapeutic armamentarium.

ADP ribose polymerase inhibitors for treating non-small cell lung cancer: new additions to the pharmacotherapeutic armamentarium.

Journal: Expert opinion on pharmacotherapy

Published: February 20, 2020

Resistin is associated with overall survival in non-small cell lung cancer patients during nivolumab treatment.

Resistin is associated with overall survival in non-small cell lung cancer patients during nivolumab treatment.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: December 05, 2019

Showing 1-12 of 55

Last Updated: 09/26/2026